11 research outputs found
HUNOR: The Collaboration of Hungarian Open Access Repositories
No full textAbstractThe HUNOR (HUNgarian Open Access Repositories) consortium was established in 2008 by the libraries of Hungarian higher education institutions and the Library of the Hungarian Academy of Sciences to advance national open access practices. The members of HUNOR are dedicated to promoting Hungarian research both nationally and internationally and to achieving effective dissemination of scientific outputs through the implementation of a national infrastructure of open access repositories. Other proposed activities include the organization of a methodology centre, adopting international know-how and standards, the establishment of complementary scientific communication channels, and international relations.As coordinator of HUNOR, the author presents an overview of the Hungarian research repository infrastructure, the achievements, difficulties and goals of the HUNOR Collaboration
Subprime Consumer Credit Demand: Evidence from a Lender's Pricing Experiment
No full textUsing a unique panel data set from a U.K. credit card company, we analyze the interest rate sensitivity of subprime credit card borrowers. In addition to all individual transactions and loan terms, we have access to details of a randomized interest rate experiment conducted by the lender on existing (inframarginal) loans. For the whole sample, we estimate a statistically significant £3.4 reduction in monthly credit demand in response to a five percentage point increase in interest rates. This aggregate response is small, but it masks very interesting heterogeneity in the sample. We find that only low-risk borrowers who fully utilize their credit cards lower their credit demand significantly when faced with an increase in interest rates. We also document that a five percentage point increase in interest rates generates significant additional revenue for the lender without inducing delinquency over a short horizon. © 2013 The Author
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia
No full textFull author list omitted for brevity. For full list of authors see article.Heavy drinkers are at risk for a spectrum of histologic alcohol-related liver injury: steatosis, alcoholic steatohepatitis (ASH), alcohol-related fibrosis, and cirrhosis. Alcoholic hepatitis (AH), the clinical entity associated with severe ASH, has high short-term mortality. The standard-of-care therapy, prednisolone, has limited efficacy and many side effects; no other treatment has consistently shown survival benefit. The National Institute on Alcohol Abuse and Alcoholism (NIAAA)-funded Alcoholic Hepatitis Consortia carry out translational research on pathophysiologic mechanisms, genetic and environmental risk factors, phase II clinical trials, and development of biomarkers. The consortia members were convened by the National Institutes of Health to address diagnostic criteria and practical issues related to clinical AH research, and to develop a set of common data elements to harmonize ongoing and future trials. This was accomplished through 3 face-to-face meetings of the investigators and representatives of the National Institutes of Health, and subsequent electronic communications over the course of 6 months. Evidence for the recommendations was based on published trials and observational data from several of the consortia members. A draft manuscript was iteratively reviewed by members of the consortia. The goal was to reach agreements on recommendations and definitions that could facilitate trial design, and simultaneously be tested by research groups pooling their data. The recommendations made here are specifically directed to achieve better uniformity in clinical trials, rather than serving as clinical practice guidelines
Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease
No full textFull author list omitted for brevity. For the full list of authors, see article.OBJECTIVE: Alcoholic liver disease (ALD) is a global health problem with limited therapeutic options. Intestinal barrier integrity and the microbiota modulate susceptibility to ALD. Akkermansia muciniphila, a Gram-negative intestinal commensal, promotes barrier function partly by enhancing mucus production. The aim of this study was to investigate microbial alterations in ALD and to define the impact of A. muciniphila administration on the course of ALD. DESIGN: The intestinal microbiota was analysed in an unbiased approach by 16S ribosomal DNA (rDNA) sequencing in a Lieber-DeCarli ALD mouse model, and faecal A. muciniphila abundance was determined in a cohort of patients with alcoholic steatohepatitis (ASH). The impact of A. muciniphila on the development of experimental acute and chronic ALD was determined in a preventive and therapeutic setting, and intestinal barrier integrity was analysed. RESULTS: Patients with ASH exhibited a decreased abundance of faecal A. muciniphila when compared with healthy controls that indirectly correlated with hepatic disease severity. Ethanol feeding of wild-type mice resulted in a prominent decline in A. muciniphila abundance. Ethanol-induced intestinal A. muciniphila depletion could be restored by oral A. muciniphila supplementation. Furthermore, A. muciniphila administration when performed in a preventive setting decreased hepatic injury, steatosis and neutrophil infiltration. A. muciniphila also protected against ethanol-induced gut leakiness, enhanced mucus thickness and tight-junction expression. In already established ALD, A. muciniphila used therapeutically ameliorated hepatic injury and neutrophil infiltration. CONCLUSION: Ethanol exposure diminishes intestinal A. muciniphila abundance in both mice and humans and can be recovered in experimental ALD by oral supplementation. A. muciniphila promotes intestinal barrier integrity and ameliorates experimental ALD. Our data suggest that patients with ALD might benefit from A. muciniphila supplementation
Detection of opinion spam with character n-grams
No full textThe final publication is available at Springer via http://dx.doi.org/10.1007/978-3-319-18117-2_21In this paper we consider the detection of opinion spam as a stylistic classi cation task because, given a particular domain, the deceptive and truthful opinions are similar in content but di ffer in the way opinions are written (style). Particularly, we propose using character ngrams as features since they have shown to capture lexical content as well as stylistic information. We evaluated our approach on a standard
corpus composed of 1600 hotel reviews, considering positive and negative
reviews. We compared the results obtained with character n-grams against the ones with word n-grams. Moreover, we evaluated the e ffectiveness of character n-grams decreasing the training set size in order to simulate real training conditions. The results obtained show that character n-grams are good features for the detection of opinion spam; they seem to be able to capture better than word n-grams the content of deceptive opinions and the writing style of the deceiver. In particular,
results show an improvement of 2:3% and 2:1% over the word-based representations in the detection of positive and negative deceptive opinions
respectively. Furthermore, character n-grams allow to obtain a good performance
also with a very small training corpus. Using only 25% of the training set, a Na ve Bayes classi er showed F1 values up to 0.80 for both opinion polarities.This work is the result of the collaboration in the frame-work of the WIQEI IRSES project (Grant No. 269180) within the FP7 Marie Curie. The second author was partially supported by the LACCIR programme under project ID R1212LAC006. Accordingly, the work of the third author was in the framework the DIANA-APPLICATIONS-Finding Hidden Knowledge inTexts: Applications (TIN2012-38603-C02-01) project, and the VLC/CAMPUS Microcluster on Multimodal Interaction in Intelligent Systems.Hernández Fusilier, D.; Montes Gomez, M.; Rosso, P.; Guzmán Cabrera, R. (2015). Detection of opinion spam with character n-grams. En Computational Linguistics and Intelligent Text Processing: 16th International Conference, CICLing 2015, Cairo, Egypt, April 14-20, 2015, Proceedings, Part II. Springer International Publishing. 285-294. https://doi.org/10.1007/978-3-319-18117-2_21S285294Blamey, B., Crick, T., Oatley, G.: RU:-) or:-(? character-vs. word-gram feature selection for sentiment classification of OSN corpora. Research and Development in Intelligent Systems XXIX, 207–212 (2012)Drucker, H., Wu, D., Vapnik, V.N.: Support Vector Machines for Spam Categorization. IEEE Transactions on Neural Networks 10(5), 1048–1054 (2002)Feng, S., Banerjee, R., Choi, Y.: Syntactic Stylometry for Deception Detection. Association for Computational Linguistics, short paper. ACL (2012)Feng, S., Xing, L., Gogar, A., Choi, Y.: Distributional Footprints of Deceptive Product Reviews. In: Proceedings of the 2012 International AAAI Conference on WebBlogs and Social Media (June 2012)Gyongyi, Z., Garcia-Molina, H., Pedersen, J.: Combating Web Spam with Trust Rank. In: Proceedings of the Thirtieth International Conference on Very Large Data Bases, vol. 30, pp. 576–587. VLDB Endowment (2004)Hall, M., Eibe, F., Holmes, G., Pfahringer, B., Reutemann, P., Witten, I.: The WEKA Data Mining Software: an Update. SIGKDD Explor. Newsl. 10–18 (2009)Hernández-Fusilier, D., Guzmán-Cabrera, R., Montes-y-Gómez, M., Rosso, P.: Using PU-learning to Detect Deceptive Opinion Spam. In: Proceedings of the 4th Workshop on Computational Approaches to Subjectivity, Sentiment and Social Media Analysis for Computational Linguistics: Human Language Technologies, Atlanta, Georgia, USA, pp. 38–45 (2013)Hernández-Fusilier, D., Montes-y-Gómez, M., Rosso, P., Guzmán-Cabrera, R.: Detecting Positive and Negative Deceptive Opinions using PU-learning. Information Processing & Management (2014), doi:10.1016/j.ipm.2014.11.001Jindal, N., Liu, B.: Opinion Spam and Analysis. In: Proceedings of the International Conference on Web Search and Web Data Mining, pp. 219–230 (2008)Jindal, N., Liu, B., Lim, E.: Finding Unusual Review Patterns Using Unexpected Rules. In: Proceedings of the 19th ACM International Conference on Information and Knowledge Management, CIKM 2010, pp. 210–220(October 2010)Kanaris, I., Kanaris, K., Houvardas, I., Stamatatos, E.: Word versus character n-grams for anti-spam filtering. International Journal on Artificial Intelligence Tools 16(6), 1047–1067 (2007)Lim, E.P., Nguyen, V.A., Jindal, N., Liu, B., Lauw, H.W.: Detecting Product Review Spammers Using Rating Behaviours. In: CIKM, pp. 939–948 (2010)Liu, B.: Sentiment Analysis and Opinion Mining. Synthesis Lecture on Human Language Technologies. Morgan & Claypool Publishers (2012)Mukherjee, A., Liu, B., Wang, J., Glance, N., Jindal, N.: Detecting Group Review Spam. In: Proceedings of the 20th International Conference Companion on World Wide Web, pp. 93–94 (2011)Ntoulas, A., Najork, M., Manasse, M., Fetterly, D.: Detecting Spam Web Pages through Content Analysis. Transactions on Management Information Systems (TMIS), 83–92 (2006)Ott, M., Choi, Y., Cardie, C., Hancock, J.T.: Finding Deceptive Opinion Spam by any Stretch of the Imagination. In: Proceedings of the 49th Annual Meeting of the Association for Computational Linguistics: Human Language Technologies, Portland, Oregon, USA, pp. 309–319 (2011)Ott, M., Cardie, C., Hancock, J.T.: Negative Deceptive Opinion Spam. In: Proceedings of the 2013 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Atlanta, Georgia, USA, pp. 309–319 (2013)Raymond, Y.K., Lau, S.Y., Liao, R., Chi-Wai, K., Kaiquan, X., Yunqing, X., Yuefeng, L.: Text Mining and Probabilistic Modeling for Online Review Spam Detection. ACM Transactions on Management Information Systems 2(4), Article: 25, 1–30 (2011)Stamatatos, E.: On the robustness of authorship attribution based on character n-gram features. Journal of Law & Policy 21(2) (2013)Wu, G., Greene, D., Cunningham, P.: Merging Multiple Criteria to Identify Suspicious Reviews. In: RecSys 2010, pp. 241–244 (2010)Xie, S., Wang, G., Lin, S., Yu, P.S.: Review Spam Detection via Time Series Pattern Discovery. In: Proceedings of the 21st International Conference Companion on World Wide Web, pp. 635–636 (2012)Zhou, L., Sh, Y., Zhang, D.: A Statistical Language Modeling Approach to Online Deception Detection. IEEE Transactions on Knowledge and Data Engineering 20(8), 1077–1081 (2008
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
No full textBackground: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
No full textBACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
No full textBACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus.METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-analysis.RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (<45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]).CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02065791
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
No full textCanagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Tria
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
No full textBackground:
Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention).
Methods:
In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care.
Results:
Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67–0.95];
P
=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49–0.94]) and secondary (HR, 0.85 [95% CI, 0.69–1.06]) prevention groups (
P
for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61–1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59–1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56–1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (
P
for interaction >0.5 for each outcome).
Conclusions:
Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease.
Clinical Trial Registration:
URL:
https://www.clinicaltrials.gov
. Unique identifier: NCT02065791
